S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NASDAQ:COLL

Collegium Pharmaceutical (COLL) Stock Forecast, Price & News

$22.53
+0.15 (+0.67%)
(As of 05/26/2023 ET)
Compare
Today's Range
$22.24
$22.74
50-Day Range
$22.08
$24.89
52-Week Range
$14.89
$30.22
Volume
219,234 shs
Average Volume
363,971 shs
Market Capitalization
$779.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

Collegium Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
55.3% Upside
$35.00 Price Target
Short Interest
Bearish
19.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.78
Upright™ Environmental Score
News Sentiment
0.81mentions of Collegium Pharmaceutical in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.11 M Sold Last Quarter
Proj. Earnings Growth
16.05%
From $4.86 to $5.64 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

310th out of 1,018 stocks

Pharmaceutical Preparations Industry

132nd out of 498 stocks


COLL stock logo

About Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Stock News Headlines

NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
Piper Sandler Sticks to Its Buy Rating for Ironwood Pharma (IRWD)
2030, Allergy Treatment Market Research
NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
Piper Sandler Keeps Their Buy Rating on Ironwood Pharma (IRWD)
Pacira (PCRX) Lags Q1 Earnings Estimates
See More Headlines
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Company Calendar

Last Earnings
5/04/2023
Today
5/27/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COLL
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+55.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-25,000,000.00
Pretax Margin
-5.82%

Debt

Sales & Book Value

Annual Sales
$463.93 million
Cash Flow
$8.22 per share
Book Value
$5.20 per share

Miscellaneous

Free Float
33,318,000
Market Cap
$779.54 million
Optionable
Optionable
Beta
0.81

Key Executives

  • Joseph J. CiaffoniJoseph J. Ciaffoni
    President, Chief Executive Officer & Director
  • Colleen TupperColleen Tupper
    Chief Financial Officer & Executive Vice President
  • Scott Sudduth
    Executive Vice President-Technical Operations
  • Thomas B. Smith
    Chief Medical Officer & Executive Vice President
  • Scott DreyerScott Dreyer
    Chief Commercial Officer & Executive VP













COLL Stock - Frequently Asked Questions

Should I buy or sell Collegium Pharmaceutical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" COLL shares.
View COLL analyst ratings
or view top-rated stocks.

What is Collegium Pharmaceutical's stock price forecast for 2023?

2 analysts have issued 12-month price targets for Collegium Pharmaceutical's shares. Their COLL share price forecasts range from $35.00 to $35.00. On average, they expect the company's share price to reach $35.00 in the next year. This suggests a possible upside of 55.3% from the stock's current price.
View analysts price targets for COLL
or view top-rated stocks among Wall Street analysts.

How have COLL shares performed in 2023?

Collegium Pharmaceutical's stock was trading at $23.20 on January 1st, 2023. Since then, COLL shares have decreased by 2.9% and is now trading at $22.53.
View the best growth stocks for 2023 here
.

When is Collegium Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our COLL earnings forecast
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings data on Thursday, May, 4th. The specialty pharmaceutical company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.20 by $0.02. Collegium Pharmaceutical had a negative net margin of 5.59% and a positive trailing twelve-month return on equity of 62.88%.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $569.68 million.

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.80%), Rubric Capital Management LP (9.46%), Principal Financial Group Inc. (4.48%), State Street Corp (3.91%), Renaissance Technologies LLC (3.49%) and Dimensional Fund Advisors LP (2.77%). Insiders that own company stock include Alison B Fleming, Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends
.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $22.53.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $779.54 million and generates $463.93 million in revenue each year. The specialty pharmaceutical company earns $-25,000,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

The company employs 152 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.

This page (NASDAQ:COLL) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -